| Trial ID: | L3311 |
| Source ID: | NCT01013766
|
| Associated Drug: |
Gsk1362885
|
| Title: |
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK1362885 in Type 2 Diabetics
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: GSK1362885|DRUG: GSK1362885
|
| Outcome Measures: |
Primary: Safety and tolerability assessments including adverse events and clinical laboratory tests, 7 Days|Pharmacodynamics following oral administration (glucose, insulin, c-peptide), 24 hours|Pharmacokinetic parameters: AUC, Cmax, Tmax, t1/2, tlag, Cl/F, and V/F, 24 hours | Secondary: Pharmacodynamics following BID administration (glucose, insulin, c-peptide), 24 hours|Relationship between pharmacokinetic and pharmacodynamic parameters, 24 hours
|
| Sponsor/Collaborators: |
Sponsor: GlaxoSmithKline
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
23
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2009-08-13
|
| Completion Date: |
2009-11-20
|
| Results First Posted: |
|
| Last Update Posted: |
2017-06-20
|
| Locations: |
GSK Investigational Site, Phoenix, Arizona, 85013, United States|GSK Investigational Site, Saint Paul, Minnesota, 55114-1067, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01013766
|
